
MHC-Associated Peptide Proteomics (MAPPs) as a Tool for Assessment of Immunogenicity Risk Potential of Therapeutic ...
Biotherapeutic monoclonal antibodies (mAbs) can elicit unwanted immune responses in patients, potentially leading to anti-drug antibody (ADA) formation, reduced efficacy, or safety concerns. The major histocompatibility complex (MHC)-associated peptide …